The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Background CD47 is a broadly expressed cell surface glycoprotein associated with immune evasion. Interaction with the inhibitory receptor signal regulatory protein alpha (SIRPα), primarily expressed on myeloid cells, normally serves to restrict effector function (eg, phagocytosis and immune cell hom...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Li Zhang, Emmanuel Normant, Ammar Adam, Marisa O Peluso, Caroline M Armet, Rachel W O’Connor, Benjamin H Lee, Andrew C Lake, Scott C Chappel, Jonathan A Hill, Vito J Palombella, Pamela M Holland, Alison M Paterson
التنسيق: مقال
اللغة:English
منشور في: BMJ Publishing Group 2020-05-01
سلاسل:Journal for ImmunoTherapy of Cancer
الوصول للمادة أونلاين:https://jitc.bmj.com/content/8/1/e000413.full

الانترنت

https://jitc.bmj.com/content/8/1/e000413.full

مواد مشابهة